Some studies have demonstrated the efficacy of blocking IL-6 pathway by monoclonal antibodies in murine models of cancer cachexia (tocilizumab) and in non-small-cell lung carcinoma (NSCLC)-patients (ALD518), leading to an improvement of muscle mass and fitness [55,56]. Here, IL6 is linked to cancer.